Torrent Pharmaceuticals Limited

Torrent Pharma receives Corrigendum Order for J.B. Chemicals Amalgamation from NCLT

Torrent Pharmaceuticals has received a Corrigendum Order from the NCLT, Ahmedabad Bench, regarding the proposed amalgamation of J.B. Chemicals & Pharmaceuticals Limited. The order was issued on March 24, 2026, and uploaded on the NCLT website on March 25, 2026.

Torrent Pharma Amalgamation: NCLT Ahmedabad Uploads Order for J.B. Chemicals Scheme

Torrent Pharmaceuticals Limited has received an order from the Hon'ble National Company Law Tribunal (NCLT), Ahmedabad Bench, regarding the proposed amalgamation of J.B. Chemicals & Pharmaceuticals Limited. The NCLT uploaded the order on March 23rd, 2026, following an earlier intimation on June 29th, 2025.

Torrent Pharma Launches Semaglutide Brands Sembolic and Semalix in India

Torrent Pharma launched Semaglutide brands Sembolic (oral) and Semalix (injectable) in India on March 21, 2026. This marks the company's entry into the GLP-1 therapy segment for type-2 diabetes and obesity. Semalix injectable is priced at ₹3,999 per month. Torrent Pharma is the first Indian company to offer generic oral semaglutide.

Torrent Pharma Announces Special Window for Physical Share Transfers & Dematerialization

Torrent Pharmaceuticals Limited has opened a special window for the transfer and dematerialization of physical shares. This announcement was published in the Financial Express on March 10, 2026.

Torrent Pharma to attend Investor Meetings in Singapore, Hong Kong & London in March 2026

Torrent Pharmaceuticals will participate in investor meetings in Singapore from March 2-4, 2026, Hong Kong from March 5-6, 2026, and London from March 9-12, 2026. The meetings will be with institutional investors and will include both group and one-on-one sessions. The schedule is subject to change based on company or investor exigencies.

Torrent Pharma releases Q3 FY26 earnings call transcript

Torrent Pharmaceuticals Limited has published the transcript of its conference call discussing financial results for Q3 and the nine months ended December 31, 2025. The transcript is available on the company's investor relations website.

Torrent Pharma places audio recording of Q3 FY26 investor call on website

Torrent Pharmaceuticals Limited has released the audio recording of its conference call discussing financial results for the quarter and nine months ended December 31, 2025. The recording is available on the company's website.

Torrent Pharma declares ₹29 interim dividend; Q3 FY26 consolidated profit at ₹635 Cr.

Torrent Pharmaceuticals Limited announced its Q3 FY26 results. The company reported a consolidated net profit of ₹635 crore, up from ₹503 crore in Q3 FY25. Consolidated revenue from operations rose to ₹3,303 crore from ₹2,809 crore. An interim dividend of ₹29 per share was declared, payable around March 6, 2026.

Torrent Pharma Approves Interim Dividend of ₹29/Share, Reports Q3 FY26 Results

Torrent Pharmaceuticals Limited approved its Q3 FY26 financial results and declared an interim dividend of ₹29 per equity share. The dividend is expected to be paid around March 6, 2026. The Board meeting concluded on February 13, 2026.

Torrent Pharma Q3 FY26 Revenue Rises 18% to ₹3,303 Crore

Torrent Pharma's Q3 FY26 consolidated revenue grew 18% to ₹3,303 crore. Year-to-date revenue increased 14% to ₹9,783 crore. Growth was driven by India (up 14% in Q3), the US (up 19% in Q3), and Brazil (up 27% in Q3). The results were presented to analysts on February 13, 2026.

Torrent Pharma Approves Interim Dividend of ₹29/Share; Q3 FY26 Results Announced

Torrent Pharmaceuticals declared an interim dividend of ₹29 per share, payable by March 6, 2026. The company reported its Q3 FY26 financial results. Significant progress was made in acquiring JB Pharma, with control established and a merger scheme underway. Exceptional items were related to the JB Pharma acquisition.

Torrent Pharma Approves Interim Dividend of ₹29/Share; Q3 FY26 Results Announced

Torrent Pharmaceuticals announced an interim dividend of ₹29 per share, payable around March 6, 2026. The company reported Q3 FY26 standalone revenue of ₹2599 crore and net profit of ₹577 crore. Consolidated revenue was ₹3303 crore with a net profit of ₹635 crore. The acquisition and proposed merger of JB Pharma are progressing.

Torrent Pharma to Participate in Multiple Investor Meets from Feb 16-24

Torrent Pharmaceuticals will attend investor meetings from February 16-19, 2026, in Mumbai. The company will also participate in the Kotak - Chasing Growth 2026 Investor Conference on February 23rd and the IIFL - Enterprising India Investor Conference on February 24th, 2026. These are group and one-on-one meetings.

Torrent Pharma Acquires Additional 0.06% Stake in JB Chemicals, Total Holding Reaches 48.80%

Torrent Pharmaceuticals acquired an additional 0.06% stake in JB Chemicals on February 3, 2026. This acquisition fulfills the terms of previous share purchase agreements. Following this, Torrent Pharma's total holding in JB Chemicals stands at 48.80% of its equity share capital.

Torrent Pharma Sets Feb 19, 2026 as Record Date for Interim Dividend

Torrent Pharmaceuticals Limited has set February 19, 2026, as the record date for interim dividend payment. The Board will decide on the dividend declaration in a meeting on February 13, 2026. This is for equity shareholders of ₹5 each.

Torrent Pharma Schedules Investor Conference Call for Q3 FY26 Results on Feb 13

Torrent Pharmaceuticals Limited will host an investor and analyst conference call on February 13, 2026, at 06:30 PM. The call will focus on discussing the company's financial performance for the quarter that ended on December 31, 2025.

Torrent Pharma Appoints Geena Malhotra as Chief Technology Officer

Torrent Pharmaceuticals Limited appointed Geena Malhotra as Chief Technology Officer, effective February 1, 2026. Malhotra brings nearly four decades of global pharmaceutical experience, including her previous role as Global CTO at Cipla Ltd. The appointment was approved by the Board of Directors on January 30, 2026.

Torrent Pharma to Shift Registered Office in Ahmedabad Effective January 29, 2026

Torrent Pharmaceuticals Limited will shift its registered office from "Torrent House" to "Avirat" in Ahmedabad. The relocation is effective from January 29, 2026, following the Board of Directors' approval on January 27, 2026.

Torrent Pharma Acquires Additional 2.36% Stake in JB Chemicals, Total Holding Reaches 48.75%

Torrent Pharmaceuticals acquired an additional 2.36% stake in JB Chemicals on January 23rd, 2026, from employees. The company's total holding in JB Chemicals now stands at 48.75% on a fully diluted basis.

Torrent Pharma's Dahej Facility Cleared by USFDA with Zero Observations

Torrent Pharmaceuticals Limited's Dahej manufacturing facility was inspected by the USFDA from January 19-23, 2026. The inspection concluded with zero observations, signifying a positive outcome for the company's compliance and production capabilities.

Torrent Pharma Completes Acquisition of 46.39% Stake in J.B. Chemicals for ₹7,44,81,519 Shares

Torrent Pharmaceuticals completed the acquisition of 7,44,81,519 equity shares, representing 46.39% of J.B. Chemicals, on January 21, 2026. The company now holds control and is classified as a promoter. This follows earlier agreements dated June 29, 2025, and July 3, 2025.

Torrent Pharma Allots NCDs Worth ₹79,900 Crore Across Four Series

Torrent Pharmaceuticals Limited has allotted Non-Convertible Debentures (NCDs) worth ₹79,900 crore across four series on January 19, 2026. The NCDs range in tenure from 2 to nearly 5 years with annual coupon rates from 7.45% to 7.80%. The issuance was conducted via private placement and will be listed on NSE.

Torrent Pharma Raises ₹1,500 Crore Via Commercial Paper Issuance

Torrent Pharmaceuticals Limited has successfully issued Commercial Papers worth ₹1,500 Crores. The issuance comprises 30,000 CPs with a face value of ₹5,00,000 each. The papers mature on December 22, 2026, carrying an interest rate of 7.20%.

Torrent Pharma's Long-Term Credit Rating Reaffirmed at ICRA AA+ (Stable)

ICRA has reaffirmed Torrent Pharmaceuticals Limited's long-term credit rating for banking facilities and NCDs at [ICRA] AA+ (Stable). The rating for the commercial paper programme has also been reaffirmed for existing amounts and assigned for enhanced amounts at [ICRA] A1+.

Torrent Pharma Approves Issuance of NCDs Worth ₹12,500 Crore via Private Placement

Torrent Pharmaceuticals Limited approved issuing NCDs worth up to ₹12,500 crore on a private placement basis. The STSRC committee approved the issuance on January 5th, 2026. The NCDs will be listed on NSE's Wholesale Debt Market Segment.

Torrent Pharma Approves Issuance of NCDs Worth ₹12,500 Crore

Torrent Pharmaceuticals Limited's STSRC approved the issuance of Secured, Rated, Listed, Redeemable Non-Convertible Debentures (NCDs) worth up to ₹12,500 Crore. The NCDs will be issued in tranches via private placement and listed on NSE's WDM. A security cover of 1.1x will be provided.

Torrent Pharma's Credit Rating Affirmed at IND AA+(Stable); IND A1+ Assigned to Commercial Paper

India Ratings affirmed Torrent Pharmaceuticals' credit rating at IND AA+(Stable) for banking facilities, issuer rating, and NCDs. The company was also assigned an IND A1+ rating for its proposed Commercial Paper.

Torrent Pharma Closes Trading Window from Jan 1, 2026 for Q3 FY26 Results

Torrent Pharmaceuticals Limited will close its trading window for designated persons from January 1, 2026. The window will reopen 48 hours after the submission of Q3 FY26 financial results. This is a routine regulatory disclosure.

Torrent Pharma Redeems ₹200 Crore Commercial Papers on Dec 23, 2025

Torrent Pharmaceuticals Limited has fully redeemed and repaid Commercial Papers worth ₹200 crore on December 23, 2025. This action pertains to CPs issued under ISIN: INE685A14179.

Torrent Pharma Redeems ₹200 Crore Commercial Papers on Dec 16, 2025

Torrent Pharmaceuticals Limited has fully redeemed and repaid Commercial Papers worth ₹200 crore on December 16, 2025. This action pertains to CPs issued under ISIN INE685A14161.

Torrent Pharma Redeems ₹142.84 Crore NCDs on Dec 12, 2025

Torrent Pharmaceuticals Limited redeemed ₹142.84 crore of its Secured Redeemable Non-Convertible Debentures on December 12, 2025. This is part of a larger ₹1000 crore NCD issuance.

Torrent Pharmaceuticals Receives ESG Rating of 70 from NSE Sustainability

Torrent Pharmaceuticals receives an ESG rating of 70 from NSE Sustainability Ratings and Analytics Limited, as per a regulatory filing.

Torrent Pharma acquires equity shares of J.B. Chemicals under open offer

Torrent Pharma acquires 1,317 equity shares of J.B. Chemicals & Pharmaceuticals Limited on December 5, 2025, at ₹1,639.18 per share via open offer.

Torrent Pharma Announces Special Window for Physical Share Transfer

Torrent Pharma announced a special window from 7 July 2025 to 6 January 2026 for re-lodgement of physical share transfer requests that were previously rejected due to deficiencies.

Torrent Pharmaceuticals Receives Order from GST Authority

Torrent Pharma received an order from GST authority with a penalty of ₹ 41.33 crore. The company will appeal and does not expect material financial impact.

Newspaper Publication: Transfer of Shares to IEPF

Torrent Pharma announced on 27 Nov 25 regarding transfer of shares to IEPF due to unclaimed dividends for 7+ years, in compliance with Companies Act, requesting shareholders to claim by 4 Mar 26.

Torrent Pharmaceuticals Announces Conference Call Transcript for Q2 FY26

Torrent Pharmaceuticals released the transcript of its conference call with analysts and investors, discussing the financial results for the quarter and half year ended September 30, 2025. The transcript is available on the company website.

Torrent Pharmaceuticals releases audio recording of Q2 FY26 earnings conference call

Torrent Pharmaceuticals released the audio recording of its conference call with analysts/investors regarding the financial results for the quarter and half year ended 30th September 2025.

Torrent Pharma Reports Strong Q2 & H1 FY26 Results; Progresses on J.B. Chemicals Acquisition

Torrent Pharma announced strong Q2 and H1 FY26 results with increased revenue and profit. It also progressed significantly on the J.B. Chemicals acquisition, securing crucial regulatory approvals.

Torrent Pharma releases investor presentation for Q2 & H1 FY26 consolidated financial results

Torrent Pharmaceuticals released its investor presentation for Q2 and H1 FY26, showcasing strong consolidated revenue growth across all key markets, with total revenues up 14% for Q2 and 13% for H1.

Torrent Pharma Reports Strong Q2 & H1 FY26 Results; JB Pharma Acquisition Progresses

Torrent Pharmaceuticals reported strong Q2 and H1 FY26 financial results with significant profit growth. The acquisition of JB Chemicals & Pharmaceuticals Limited is progressing well, having received key regulatory approvals.

Torrent Pharma Announces Investor/Analyst Conference Call on 7 Nov 2025

Torrent Pharma announces a conference call with investors/analysts on November 7, 2025, to discuss the financial results for the quarter and half-year ended September 30, 2025. Dial-in details provided.

CCI approves Torrent Pharma's acquisition of J. B. Chemicals from KKR

CCI approves Torrent Pharma's acquisition of J. B. Chemicals & Pharmaceuticals from KKR on 21st October, 2025, subject to compliance with voluntary modifications.

ICRA Reaffirms Torrent Pharma's Credit Ratings at [ICRA] AA+ (Stable) and [ICRA] A1+

ICRA reaffirmed Torrent Pharmaceuticals' long-term credit rating at [ICRA] AA+ (Stable) and assigned the same for proposed NCDs, while reaffirming Commercial Paper at [ICRA] A1+.

Torrent Pharmaceuticals receives 'IND AA+(Stable)' credit rating from India Ratings

Torrent Pharma's credit rating affirmed and assigned at IND AA+(Stable) by India Ratings for existing facilities, NCDs, and proposed NCDs.

Torrent Pharma receives ₹6.63 crore demand notice from NPPA for alleged overcharging

Torrent Pharma received a demand notice from NPPA for ₹6.63 crore for alleged overcharging of five drugs from Jan-16 to Nov-18; company assesses no material impact.

Torrent Pharmaceuticals issues Commercial Papers worth ₹200 Crore

Torrent Pharma Receives Approval from South Africa Competition Commission

Torrent Pharma redeems Commercial Papers worth ₹200 crores

Torrent Pharmaceuticals issues Commercial Papers worth ₹200 Crores